| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Lixte Biotech Hldgs (NASDAQ:LIXT) reported quarterly losses of $(0.29) per share. This is a 35.56 percent increase over losses ...